M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Development of drought-resistant cultivars using physiomorphological traits in rice
Shu Fukai,Mark E. Cooper +1 more
TL;DR: In this article, the authors describe patterns of water-stress development in rice fields, review genetic variation in physio-morphological traits for drought resistance in rice, and suggest how knowledge of stress physiology can contribute to plant breeding programmes that aim to increase yield in water-limiting environments.
Journal ArticleDOI
New-Onset Diabetes in Covid-19.
Francesco Rubino,Stephanie A. Amiel,Paul Zimmet,K. George M.M. Alberti,Stefan R. Bornstein,Robert H. Eckel,Geltrude Mingrone,Bernhard O. Boehm,Mark E. Cooper,Zhonglin Chai,Stefano Del Prato,Linong Ji,David Hopkins,William H. Herman,Kamlesh Khunti,Jean Claude Mbanya,Eric Renard +16 more
TL;DR: A large number of patients with or at risk of diabetes and metabolic complications of preexisting diabetes, including diabetic ketoacidosis and h...
Journal ArticleDOI
Human Monocytes Engage an Alternative Inflammasome Pathway
Moritz M. Gaidt,Thomas S. Ebert,Dhruv Chauhan,Tobias Schmidt,Jonathan L. Schmid-Burgk,Francesca Rapino,Avril A. B. Robertson,Mark E. Cooper,Thomas Graf,Veit Hornung,Veit Hornung +10 more
TL;DR: A pivotal role is proposed for this signaling cascade in TLR4-driven, IL-1β-mediated immune responses and immunopathology in humans and it is reported that this constituted a species-specific response that is not observed in the murine system.
Journal ArticleDOI
Genome-wide association study identifies five loci associated with lung function.
Emmanouela Repapi,Ian Sayers,Louise V. Wain,Paul Burton,Toby Johnson,Ma'en Obeidat,Jing Hua Zhao,Adaikalavan Ramasamy,Guangju Zhai,Veronique Vitart,Jennifer E. Huffman,Wilmar Igl,E Albrecht,Panagiotis Deloukas,John Henderson,Raquel Granell,Wendy L. McArdle,Alicja R. Rudnicka,Inês Barroso,Loos Rjf.,Nicholas J. Wareham,Linda Mustelin,Taina Rantanen,Ida Surakka,Ida Surakka,Medea Imboden,H E Wichmann,Ivica Grković,Stipan Janković,Lina Zgaga,Hartikainen A-L.,Hartikainen A-L.,Hartikainen A-L.,Leena Peltonen,Leena Peltonen,Leena Peltonen,Ulf Gyllensten,Åsa Johansson,Ghazal Zaboli,Harry Campbell,Sarah H. Wild,James F. Wilson,Sven Gläser,Georg Homuth,Henry Völzke,Massimo Mangino,Nicole Soranzo,Nicole Soranzo,Tim D. Spector,Ozren Polasek,Igor Rudan,Igor Rudan,Alan F. Wright,Markku Heliövaara,Samuli Ripatti,Samuli Ripatti,Anneli Pouta,Åsa Torinsson Naluai,Olin A-C.,Kjell Torén,Mark E. Cooper,Alan James,Lyle J. Palmer,Lyle J. Palmer,Aroon D. Hingorani,S.G. Wannamethee,Peter H. Whincup,George Davey Smith,Shah Ebrahim,Tricia M. McKeever,Ian D. Pavord,Andrew K. MacLeod,Andrew D. Morris,David J. Porteous,Cyrus Cooper,Cyrus Cooper,Elaine M. Dennison,Seif O. Shaheen,Stefan Karrasch,E Schnabel,Holger Schulz,H Grallert,Nabila Bouatia-Naji,Jérôme Delplanque,Philippe Froguel,Philippe Froguel,John D Blakey,John Britton,Richard W Morris,John W. Holloway,Debbie A Lawlor,Jennie Hui,Jennie Hui,Fredrik Nyberg,Fredrik Nyberg,Jarvelin M-R.,Catherine Jackson,Mika Kähönen,Jaakko Kaprio,Jaakko Kaprio,Nicole Probst-Hensch,Nicole Probst-Hensch,Beate Koch,Caroline Hayward,David M. Evans,Paul Elliott,Paul Elliott,David P. Strachan,Ian P. Hall,Martin D. Tobin +109 more
TL;DR: Genome-wide association with forced expiratory volume in 1 s (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) in the SpiroMeta consortium offers mechanistic insight into pulmonary function regulation and indicate potential targets for interventions to alleviate respiratory disease.
Journal ArticleDOI
Pathogenesis, prevention, and treatment of diabetic nephropathy.
TL;DR: Specific inhibitors of the various pathways are now available, enabling investigation of the role of these processes in the pathogenesis of diabetic nephropathy and potentially to provide new therapeutic approaches for the prevention and treatment of diabetic nephropathy.